Roles of dietary phytoestrogens on the regulation of epithelial-mesenchymal transition in diverse cancer metastasis

Toxins

Volumn 8, Issue 6, 2016, Pages

  Lee, Geum A ^a   Hwang, Kyung A ^a   Choi, Kyung Chul ^a  

^a Chungbuk National University   (South Korea)

Author keywords

Cancer metastasis; Dietary phytoestrogens; DIM; Epithelial mesenchymal transition; Genistein; Kaempferol; Resveratrol

Indexed keywords

3,3'-DIINDOLYLMETHANE; ANTINEOPLASTIC AGENT; GENISTEIN; INDOLE DERIVATIVE; KAEMPFEROL; KAEMPFEROL DERIVATIVE; PHYTOESTROGEN; RESVERATROL; STILBENE DERIVATIVE;

DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENISTEIN; HUMANS; INDOLES; KAEMPFEROLS; NEOPLASM METASTASIS; NEOPLASMS; PHYTOESTROGENS; STILBENES;

EID: 84971260995     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins8060162     Document Type: Review

References (154)

1. Cragg, G.M, Grothaus, P.G, Newman, D.J. Impact of natural products on developing new anti-cancer agents. Chem. Rev. 2009, 109, 3012-3043. [CrossRef] [PubMed]
2. Fitter, A. Ecology. Making allelopathy respectable. Science 2003, 301, 1337-1338. [CrossRef] [PubMed]
3. Acharya, A, Das, I, Singh, S, Saha, T. Chemopreventive properties of indole-3-carbinol, diindolylmethane and other constituents of cardamom against carcinogenesis. Recent Pat. Food Nutr. Agric. 2010, 2, 166-177. [CrossRef] [PubMed]
4. Sporn, M.B, Suh, N. Chemoprevention of cancer. Carcinogenesis 2000, 21, 525-530. [CrossRef] [PubMed]
5. Cragg, G.M, Newman, D.J. Plants as a source of anti-cancer agents. J. Ethnopharmacol. 2005, 100, 72-79. [CrossRef] [PubMed]
6. Thakur, V.S, Deb, G, Babcook, M.A, Gupta, S. Plant phytochemicals as epigenetic modulators: Role in cancer chemoprevention. AAPS J. 2014, 16, 151-163. [CrossRef] [PubMed]
7. Allred, K.F, Yackley, K.M, Vanamala, J, Allred, C.D. Trigonelline is a novel phytoestrogen in coffee beans. J. Nutr. 2009, 139, 1833-1838. [CrossRef] [PubMed]
8. Santen, R.J, Boyd, N.F, Chlebowski, R.T, Cummings, S, Cuzick, J, Dowsett, M, Easton, D, Forbes, J.F, Key, T, Hankinson, S.E, et al. Critical assessment of new risk factors for breast cancer: Considerations for development of an improved risk prediction model. Endocr. Relat. Cancer 2007, 14, 169-187. [CrossRef] [PubMed]
9. Giacalone, P.L, Daures, J.P, Ouafik, L, Martin, P.M, Laffargue, F, Maudelonde, T. Steroids and adrenomedullin growth patterns in human ovarian cancer cells: Estrogenic-regulation assay. Gynecol. Oncol. 2003, 91, 651-656. [CrossRef]
10. Chung, S.H, Franceschi, S, Lambert, P.F. Estrogen and ERalpha: Culprits in cervical cancer? Trends Endocrinol. Metab. 2010, 21, 504-511. [CrossRef] [PubMed]
11. Hwang, K.A, Kang, N.H, Yi, B.R, Lee, H.R, Park, M.A, Choi, K.C. Genistein, a soy phytoestrogen, prevents the growth of BG-1 ovarian cancer cells induced by 17beta-estradiol or bisphenol A via the inhibition of cell cycle progression. Int. J. Oncol. 2013, 42, 733-740. [PubMed]
12. Ahn, H.N, Jeong, S.Y, Bae, G.U, Chang, M, Zhang, D, Liu, X, Pei, Y, Chin, Y.W, Lee, J, Oh, S.R, et al. Selective estrogen receptor modulation by larrea nitida on MCF-7 Cell proliferation and immature rat uterus. Biomol. Ther. 2014, 22, 347-354. [CrossRef] [PubMed]
13. Shang, Y, Brown, M. Molecular determinants for the tissue specificity of SERMs. Science 2002, 295, 2465-2468. [CrossRef] [PubMed]
14. Kuiper, G.G, Lemmen, J.G, Carlsson, B, Corton, J.C, Safe, S.H, van der Saag, P.T, van der Burg, B, Gustafsson, J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998, 139, 4252-4263. [PubMed]
15. Zhao, E, Mu, Q. Phytoestrogen biological actions on Mammalian reproductive system and cancer growth. Sci. Pharm. 2011, 79, 1-20. [CrossRef] [PubMed]
16. Harris, D.M, Besselink, E, Henning, S.M, Go, V.L, Heber, D. Phytoestrogens induce differential estrogen receptor alpha-or Beta-mediated responses in transfected breast cancer cells. Exp. Biol. Med. 2005, 230, 558-568.
17. Hsieh, C.Y, Santell, R.C, Haslam, S.Z, Helferich, W.G. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res. 1998, 58, 3833-3838. [PubMed]
18. Ju, Y.H, Fultz, J, Allred, K.F, Doerge, D.R, Helferich, W.G. Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice. Carcinogenesis 2006, 27, 856-863. [CrossRef] [PubMed]
19. Magee, P.J, Rowland, I.R. Phyto-oestrogens, their mechanism of action: Current evidence for a role in breast and prostate cancer. Br. J. Nutr. 2004, 91, 513-531. [CrossRef] [PubMed]
20. Rice, S, Whitehead, S.A. Phytoestrogens and breast cancer—Promoters or protectors? Endocr. Relat. Cancer 2006, 13, 995-1015. [CrossRef] [PubMed]
21. Kirk, C.J, Harris, R.M, Wood, D.M, Waring, R.H, Hughes, P.J. Do dietary phytoestrogens influence susceptibility to hormone-dependent cancer by disrupting the metabolism of endogenous oestrogens? Biochem. Soc. Trans. 2001, 29, 209-216. [CrossRef] [PubMed]
22. Labrie, F, Luu-The, V, Lin, S.X, Labrie, C, Simard, J, Breton, R, Belanger, A. The key role of 17 β-hydroxysteroid dehydrogenases in sex steroid biology. Steroids 1997, 62, 148-158. [CrossRef]
23. Murkies, A.L, Wilcox, G, Davis, S.R. Clinical review 92, Phytoestrogens. J. Clin. Endocrinol. Metab. 1998, 83, 297-303. [PubMed]
24. Pilsakova, L, Riecansky, I, Jagla, F. The physiological actions of isoflavone phytoestrogens. Physiol. Res. 2010, 59, 651-664. [PubMed]
25. Hutchins, A.M, Lampe, J.W, Martini, M.C, Campbell, D.R, Slavin, J.L. Vegetables, fruits, and legumes: Effect on urinary isoflavonoid phytoestrogen and lignan excretion. J. Am. Diet. Assoc. 1995, 95, 769-774. [CrossRef]
26. Milder, I.E, Arts, I.C, van de Putte, B, Venema, D.P, Hollman, P.C. Lignan contents of Dutch plant foods: A database including lariciresinol, pinoresinol, secoisolariciresinol and matairesinol. Br. J. Nutr. 2005, 93, 393-402. [CrossRef] [PubMed]
27. Zamora-Ros, R, Knaze, V, Lujan-Barroso, L, Kuhnle, G.G, Mulligan, A.A, Touillaud, M, Slimani, N, Romieu, I, Powell, N, Tumino, R, et al. Dietary intakes and food sources of phytoestrogens in the European Prospective Investigation into Cancer and Nutrition (EPIC) 24-h dietary recall cohort. Eur. J. Clin. Nutr. 2012, 66, 932-941. [CrossRef] [PubMed]
28. Heinonen, S, Nurmi, T, Liukkonen, K, Poutanen, K, Wahala, K, Deyama, T, Nishibe, S, Adlercreutz, H. In vitro metabolism of plant lignans: New precursors of mammalian lignans enterolactone and enterodiol. J. Agric. Food Chem. 2001, 49, 3178-3186. [CrossRef] [PubMed]
29. Boker, L.K, Van der Schouw, Y.T, De Kleijn, M.J, Jacques, P.F, Grobbee, D.E, Peeters, P.H. Intake of dietary phytoestrogens by Dutch women. J. Nutr. 2002, 132, 1319-1328. [PubMed]
30. Manjanatha, M, Shelton, S, Bishop, M, Lyn-Cook, L, Aidoo, A. Dietary effects of soy isoflavones daidzein and genistein on 7,12-dimethylbenz[a]anthracene-induced mammary mutagenesis and carcinogenesis in ovariectomized Big Blue transgenic rats. Carcinogenesis 2006, 27, 1970-1979. [CrossRef] [PubMed]
31. Sobolev, V.S, Horn, B.W, Potter, T.L, Deyrup, S.T, Gloer, J.B. Production of stilbenoids and phenolic acids by the peanut plant at early stages of growth. J. Agric. Food Chem. 2006, 54, 3505-3511. [CrossRef] [PubMed]
32. Jang, M, Cai, L, Udeani, G.O, Slowing, K.V, Thomas, C.F, Beecher, C.W, Fong, H.H, Farnsworth, N.R, Kinghorn, A.D, Mehta, R.G, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275, 218-220. [CrossRef] [PubMed]
33. Heerboth, S, Housman, G, Leary, M, Longacre, M, Byler, S, Lapinska, K, Willbanks, A, Sarkar, S. EMT and tumor metastasis. Clin. Transl. Med. 2015, 4. [CrossRef] [PubMed]
34. Spano, D, Heck, C, De Antonellis, P, Christofori, G, Zollo, M. Molecular networks that regulate cancer metastasis. Semin. Cancer Biol. 2012, 22, 234-249. [CrossRef] [PubMed]
35. Siegel, R.L, Miller, K.D, Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 2016, 66, 7-30. [CrossRef] [PubMed]
36. Voulgari, A, Pintzas, A. Epithelial-mesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim. Biophys. Acta 2009, 1796, 75-90. [CrossRef] [PubMed]
37. Hanahan, D, Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57-70. [CrossRef]
38. Yap, A.S, Brieher, W.M, Gumbiner, B.M. Molecular and functional analysis of cadherin-based adherens junctions. Annu. Rev. Cell Dev. Biol. 1997, 13, 119-146. [CrossRef] [PubMed]
39. Onder, T.T, Gupta, P.B, Mani, S.A, Yang, J, Lander, E.S, Weinberg, R.A. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008, 68, 3645-3654. [CrossRef] [PubMed]
40. Boyer, B, Thiery, J.P. Epithelium-mesenchyme interconversion as example of epithelial plasticity. APMIS 1993, 101, 257-268. [CrossRef] [PubMed]
41. Thiery, J.P. Cell adhesion in development: A complex signaling network. Curr. Opin. Genet. Dev. 2003, 13, 365-371. [CrossRef]
42. Miyoshi, J, Takai, Y. Structural and functional associations of apical junctions with cytoskeleton. Biochim. Biophys. Acta 2008, 1778, 670-691. [CrossRef] [PubMed]
43. Yang, J, Weinberg, R.A. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev. Cell 2008, 14, 818-829. [CrossRef] [PubMed]
44. Friedl, P, Wolf, K. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat. Rev. Cancer 2003, 3, 362-374. [CrossRef] [PubMed]
45. Polette, M, Nawrocki-Raby, B, Gilles, C, Clavel, C, Birembaut, P. Tumour invasion and matrix metalloproteinases. Crit. Rev. Oncol. Hematol. 2004, 49, 179-186. [CrossRef] [PubMed]
46. Son, H, Moon, A. Epithelial-mesenchymal Transition and Cell Invasion. Toxicol. Res. 2010, 26, 245-252. [CrossRef] [PubMed]
47. Davies, J.A. Mesenchyme to epithelium transition during development of the mammalian kidney tubule. Acta Anat. 1996, 156, 187-201. [CrossRef] [PubMed]
48. Foroni, C, Broggini, M, Generali, D, Damia, G. Epithelial-mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact. Cancer Treat. Rev. 2012, 38, 689-697. [CrossRef] [PubMed]
49. Chaffer, C.L, Weinberg, R.A. A perspective on cancer cell metastasis. Science 2011, 331, 1559-1564. [CrossRef] [PubMed]
50. Perl, A.K, Wilgenbus, P, Dahl, U, Semb, H, Christofori, G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998, 392, 190-193. [CrossRef] [PubMed]
51. Thiery, J.P, Sleeman, J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 2006, 7, 131-142. [CrossRef] [PubMed]
52. Bailey, J.M, Singh, P.K, Hollingsworth, M.A. Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. J. Cell. Biochem. 2007, 102, 829-839. [CrossRef] [PubMed]
53. Zeisberg, M, Neilson, E.G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Investig. 2009, 119, 1429-1437. [CrossRef] [PubMed]
54. Batlle, E, Sancho, E, Franci, C, Dominguez, D, Monfar, M, Baulida, J, Garcia De Herreros, A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2000, 2, 84-89. [CrossRef] [PubMed]
55. Yang, M.H, Wu, M.Z, Chiou, S.H, Chen, P.M, Chang, S.Y, Liu, C.J, Teng, S.C, Wu, K.J. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat. Cell Biol. 2008, 10, 295-305. [CrossRef] [PubMed]
56. Thiery, J.P. Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 2003, 15, 740-746. [CrossRef] [PubMed]
57. Bani-Hani, A.H, Campbell, M.T, Meldrum, D.R, Meldrum, K.K. Cytokines in epithelial-mesenchymal transition: A new insight into obstructive nephropathy. J. Urol. 2008, 180, 461-468. [CrossRef] [PubMed]
58. Han, L, Zhang, H.W, Zhou, W.P, Chen, G.M, Guo, K.J. The effects of genistein on transforming growth factor-beta1-induced invasion and metastasis in human pancreatic cancer cell line Panc-1 in vitro. Chin. Med. J. 2012, 125, 2032-2040. [PubMed]
59. Zhang, Y.E. Non-Smad pathways in TGF-β signaling. Cell Res. 2009, 19, 128-139. [CrossRef] [PubMed]
60. Bertran, E, Crosas-Molist, E, Sancho, P, Caja, L, Lopez-Luque, J, Navarro, E, Egea, G, Lastra, R, Serrano, T, Ramos, E, et al. Overactivation of the TGF-β pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells. Hepatology 2013, 58, 2032-2044. [CrossRef] [PubMed]
61. Hu, T.H, Yao, Y, Yu, S, Han, L.L, Wang, W.J, Guo, H, Tian, T, Ruan, Z.P, Kang, X.M, Wang, J, et al. SDF-1/CXCR4 promotes epithelial-mesenchymal transition and progression of colorectal cancer by activation of the Wnt/beta-catenin signaling pathway. Cancer Lett. 2014, 354, 417-426. [CrossRef] [PubMed]
62. Gitler, A.D, Lu, M.M, Jiang, Y.Q, Epstein, J.A, Gruber, P.J. Molecular markers of cardiac endocardial cushion development. Dev. Dyn. 2003, 228, 643-650. [CrossRef] [PubMed]
63. Liebner, S, Cattelino, A, Gallini, R, Rudini, N, Iurlaro, M, Piccolo, S, Dejana, E. β-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. J. Cell Biol. 2004, 166, 359-367. [CrossRef] [PubMed]
64. Wang, Z, Banerjee, S, Li, Y, Rahman, K.M, Zhang, Y, Sarkar, F.H. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006, 66, 2778-2784. [CrossRef] [PubMed]
65. Miyamoto, Y, Maitra, A, Ghosh, B, Zechner, U, Argani, P, Iacobuzio-Donahue, C.A, Sriuranpong, V, Iso, T, Meszoely, I.M, Wolfe, M.S, et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003, 3, 565-576. [CrossRef]
66. Shao, S, Zhao, X, Zhang, X, Luo, M, Zuo, X, Huang, S, Wang, Y, Gu, S, Zhao, X. Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner. Mol. Cancer 2015, 14, 28. [CrossRef] [PubMed]
67. Thayer, S.P, di Magliano, M.P, Heiser, P.W, Nielsen, C.M, Roberts, D.J, Lauwers, G.Y, Qi, Y.P, Gysin, S, Fernandez-del Castillo, C, Yajnik, V, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425, 851-856. [CrossRef] [PubMed]
68. Yoo, Y.A, Kang, M.H, Lee, H.J, Kim, B.H, Park, J.K, Kim, H.K, Kim, J.S, Oh, S.C. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res. 2011, 71, 7061-7070. [CrossRef] [PubMed]
69. Gregory, R.I, Chendrimada, T.P, Cooch, N, Shiekhattar, R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005, 123, 631-640. [CrossRef] [PubMed]
70. Filipowicz, W, Jaskiewicz, L, Kolb, F.A, Pillai, R.S. Post-transcriptional gene silencing by siRNAs and miRNAs. Curr. Opin. Struct. Biol. 2005, 15, 331-341. [CrossRef] [PubMed]
71. Siemens, H, Jackstadt, R, Hunten, S, Kaller, M, Menssen, A, Gotz, U, Hermeking, H. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011, 10, 4256-4271. [CrossRef] [PubMed]
72. Dahl, K.D.C, Dahl, R, Kruichak, J.N, Hudson, L.G. The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia 2009, 11, 1208-1215. [CrossRef]
73. Yang, D, Sun, Y, Hu, L, Zheng, H, Ji, P, Pecot, C.V, Zhao, Y, Reynolds, S, Cheng, H, Rupaimoole, R, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 2013, 23, 186-199. [CrossRef] [PubMed]
74. Yeh, Y.M, Chuang, C.M, Chao, K.C, Wang, L.H. MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1alpha. Int. J. Cancer 2013, 133, 867-878. [CrossRef] [PubMed]
75. Cheng, C.W, Wang, H.W, Chang, C.W, Chu, H.W, Chen, C.Y, Yu, J.C, Chao, J.I, Liu, H.F, Ding, S.L, Shen, C.Y. MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. Breast Cancer Res. Treat. 2012, 134, 1081-1093. [CrossRef] [PubMed]
76. Kumarswamy, R, Mudduluru, G, Ceppi, P, Muppala, S, Kozlowski, M, Niklinski, J, Papotti, M, Allgayer, H. MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int. J. Cancer 2012, 130, 2044-2053. [CrossRef] [PubMed]
77. Liu, Z, Gersbach, E, Zhang, X, Xu, X, Dong, R, Lee, P, Liu, J, Kong, B, Shao, C, Wei, J.J. miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma. Mol. Cancer Res. 2013, 11, 1314-1325. [CrossRef] [PubMed]
78. Ma, L, Teruya-Feldstein, J, Weinberg, R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449, 682-688. [CrossRef] [PubMed]
79. Zhang, L, Sun, J, Wang, B, Ren, J.C, Su, W, Zhang, T. MicroRNA-10b triggers the Epithelial-Mesenchymal Transition (EMT) of laryngeal carcinomaHep-2 cells by directly targeting the E-cadherin. Appl. Biochem. Biotechnol. 2015, 176, 33-44. [CrossRef] [PubMed]
80. Gregory, P.A, Bert, A.G, Paterson, E.L, Barry, S.C, Tsykin, A, Farshid, G, Vadas, M.A, Khew-Goodall, Y, Goodall, G.J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10, 593-601. [CrossRef] [PubMed]
81. Korpal, M, Lee, E.S, Hu, G, Kang, Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 2008, 283, 14910-14914. [CrossRef] [PubMed]
82. Dykxhoorn, D.M. MicroRNAs and metastasis: Little RNAs go a long way. Cancer Res. 2010, 70, 6401-6406. [CrossRef] [PubMed]
83. Guarino, M. Epithelial-mesenchymal transition and tumour invasion. Int. J. Biochem. Cell Biol. 2007, 39, 2153-2160. [CrossRef] [PubMed]
84. Kim, S.H, Kim, C.W, Jeon, S.Y, Go, R.E, Hwang, K.A, Choi, K.C. Chemopreventive and chemotherapeutic effects of genistein, a soy isoflavone, upon cancer development and progression in preclinical animal models. Lab. Anim. Res. 2014, 30, 143-150. [CrossRef] [PubMed]
85. Perabo, F.G, Von Low, E.C, Ellinger, J, von Rucker, A, Muller, S.C, Bastian, P.J. Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2008, 11, 6-12. [CrossRef] [PubMed]
86. Huang, J, Nasr, M, Kim, Y, Matthews, H.R. Genistein inhibits protein histidine kinase. J. Biol. Chem. 1992, 267, 15511-15515. [PubMed]
87. Ju, Y.H, Allred, K.F, Allred, C.D, Helferich, W.G. Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations. Carcinogenesis 2006, 27, 1292-1299. [CrossRef] [PubMed]
88. Pelekanou, V, Leclercq, G. Recent insights into the effect of natural and environmental estrogens on mammary development and carcinogenesis. Int. J. Dev. Biol. 2011, 55, 869-878. [CrossRef] [PubMed]
89. Pavese, J.M, Farmer, R.L, Bergan, R.C. Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev. 2010, 29, 465-482. [CrossRef] [PubMed]
90. Bao, B, Wang, Z, Ali, S, Kong, D, Li, Y, Ahmad, A, Banerjee, S, Azmi, A.S, Miele, L, Sarkar, F.H. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011, 307, 26-36. [CrossRef] [PubMed]
91. Kim, A.Y, Kwak, J.H, Je, N.K, Lee, Y.H, Jung, Y.S. Epithelial-mesenchymal transition is associatedwith acquired resistance to 5-Fluorocuracil in HT-29 colon cancer cells. Toxicol. Res. 2015, 31, 151-156. [CrossRef] [PubMed]
92. Kim, Y.S, Choi, K.C, Hwang, K.A. Genistein suppressed epithelial-mesenchymal transition and migration efficacies of BG-1 ovarian cancer cells activated by estrogenic chemicals via estrogen receptor pathway and downregulation of TGF-beta signaling pathway. Phytomedicine 2015, 22, 993-999. [CrossRef] [PubMed]
93. Dai, W, Wang, F, He, L, Lin, C, Wu, S, Chen, P, Zhang, Y, Shen, M, Wu, D, Wang, C, et al. Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial-mesenchymal transition: Partial mediation by the transcription factor NFAT1. Mol. Carcinog. 2015, 54, 301-311. [CrossRef] [PubMed]
94. Liu, J.F, Zhao, S.H, Wu, S.S. Depleting NFAT1 expression inhibits the ability of invasion and migration of human lung cancer cells. Cancer Cell Int. 2013, 13, 41. [CrossRef] [PubMed]
95. Zhang, L.L, Li, L, Wu, D.P, Fan, J.H, Li, X, Wu, K.J, Wang, X.Y, He, D.L. A novel anti-cancer effect of genistein: Reversal of epithelial mesenchymal transition in prostate cancer cells. Acta Pharmacol. Sin. 2008, 29, 1060-1068. [CrossRef] [PubMed]
96. Nonomura, S, Kanagawa, H, Makimoto, A. Chemical Constituents of Polygonaceous Plants. I. Studies on the Components of Ko-J O-Kon. (Polygonum Cuspidatum Sieb. Et Zucc.). J. Pharm. Soc. Jpn. 1963, 83, 988-990.
97. Carter, L.G, D’Orazio, J.A, Pearson, K.J. Resveratrol and cancer: Focus on in vivo evidence. Endocr. Relat. Cancer 2014, 21, R209-R225. [CrossRef] [PubMed]
98. Fremont, L. Biological effects of resveratrol. Life Sci. 2000, 66, 663-673. [CrossRef]
99. Adrian, M, Rajaei, H, Jeandet, P, Veneau, J, Bessis, R. Resveratrol oxidation in botrytis cinerea conidia. Phytopathology 1998, 88, 472-476. [CrossRef] [PubMed]
100. Ashby, J, Tinwell, H, Pennie, W, Brooks, A.N, Lefevre, P.A, Beresford, N, Sumpter, J.P. Partial and weak oestrogenicity of the red wine constituent resveratrol: Consideration of its superagonist activity in MCF-7 cells and its suggested cardiovascular protective effects. J. Appl. Toxicol. 1999, 19, 39-45. [CrossRef]
101. Bowers, J.L, Tyulmenkov, V.V, Jernigan, S.C, Klinge, C.M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000, 141, 3657-3667. [PubMed]
102. Le Corre, L, Chalabi, N, Delort, L, Bignon, Y.J, Bernard-Gallon, D.J. Resveratrol and breast cancer chemoprevention: Molecular mechanisms. Mol. Nutr. Food Res. 2005, 49, 462-471. [CrossRef] [PubMed]
103. Mitchell, S.H, Zhu, W, Young, C.Y. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 1999, 59, 5892-5895. [PubMed]
104. Pervaiz, S. Resveratrol: From grapevines to mammalian biology. FASEB J. 2003, 17, 1975-1985. [CrossRef] [PubMed]
105. Leone, L, Mazzetta, F, Martinelli, D, Valente, S, Alimandi, M, Raffa, S, Santino, I. Klebsiella pneumoniae Is Able to Trigger Epithelial-Mesenchymal Transition Process in Cultured Airway Epithelial Cells. PLoS ONE 2016, 11, e0146365. [CrossRef] [PubMed]
106. Sun, Y, Wang, H, Liu, M, Lin, F, Hua, J. Resveratrol abrogates the effects of hypoxia on cell proliferation, invasion and EMT in osteosarcoma cells through downregulation of the HIF-1α protein. Mol. Med. Rep. 2015, 11, 1975-1981. [CrossRef] [PubMed]
107. Li, W, Cao, L, Chen, X, Lei, J, Ma, Q. Resveratrol inhibits hypoxia-driven ROS-induced invasive and migratory ability of pancreatic cancer cells via suppression of the Hedgehog signaling pathway. Oncol. Rep. 2016, 35, 1718-1726. [CrossRef] [PubMed]
108. Gao, Q, Yuan, Y, Gan, H.Z, Peng, Q. Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis. Oncol. Lett. 2015, 9, 2381-2387. [CrossRef] [PubMed]
109. Li, J, Chong, T, Wang, Z, Chen, H, Li, H, Cao, J, Zhang, P, Li, H. A novel anticancer effect of resveratrol: Reversal of epithelialmesenchymal transition in prostate cancer cells. Mol. Med. Rep. 2014, 10, 1717-1724. [PubMed]
110. Ji, Q, Liu, X, Han, Z, Zhou, L, Sui, H, Yan, L, Jiang, H, Ren, J, Cai, J, Li, Q. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression. BMC Cancer 2015, 15, 97. [CrossRef] [PubMed]
111. Xu, Q, Zong, L, Chen, X, Jiang, Z, Nan, L, Li, J, Duan, W, Lei, J, Zhang, L, Ma, J, et al. Resveratrol in the treatment of pancreatic cancer. Ann. N. Y. Acad. Sci. 2015, 1348, 10-19. [CrossRef] [PubMed]
112. Li, C.W, Xia, W, Lim, S.O, Hsu, J.L, Huo, L, Wu, Y, Li, L.Y, Lai, C.C, Chang, S.S, Hsu, Y.H, et al. AKT1 inhibits epithelial-to-mesenchymal transition in breast cancer through phosphorylation-dependent Twist1 degradation. Cancer Res. 2016. [CrossRef] [PubMed]
113. Vergara, D, Valente, C.M, Tinelli, A, Siciliano, C, Lorusso, V, Acierno, R, Giovinazzo, G, Santino, A, Storelli, C, Maffia, M. Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells. Cancer Lett. 2011, 310, 1-8. [CrossRef] [PubMed]
114. Wang, H, Zhang, H, Tang, L, Chen, H, Wu, C, Zhao, M, Yang, Y, Chen, X, Liu, G. Resveratrol inhibits TGF-β1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis. Toxicology 2013, 303, 139-146. [CrossRef] [PubMed]
115. Calderon-Montano, J.M, Burgos-Moron, E, Perez-Guerrero, C, Lopez-Lazaro, M. A review on the dietary flavonoid kaempferol. Mini Rev. Med. Chem. 2011, 11, 298-344. [CrossRef] [PubMed]
116. Huang, L, Yagura, T, Chen, S. Sedative activity of hexane extract of Keampferia galanga L. and its active compounds. J. Ethnopharmacol. 2008, 120, 123-125. [CrossRef] [PubMed]
117. Boam, T. Anti-androgenic effects of flavonols in prostate cancer. Ecancermedicalscience 2015, 9, 585. [CrossRef] [PubMed]
118. Puppala, D, Gairola, C.G, Swanson, H.I. Identification of kaempferol as an inhibitor of cigarette smoke-induced activation of the aryl hydrocarbon receptor and cell transformation. Carcinogenesis 2007, 28, 639-647. [CrossRef] [PubMed]
119. Toh, M.F, Mendonca, E, Eddie, S.L, Endsley, M.P, Lantvit, D.D, Petukhov, P.A, Burdette, J.E. Kaempferol exhibits progestogenic effects in ovariectomized rats. J. Steroids Horm. Sci. 2014, 5, 136. [PubMed]
120. Kang, J.W, Kim, J.H, Song, K, Kim, S.H, Yoon, J.H, Kim, K.S. Kaempferol and quercetin, components of Ginkgo biloba extract (EGb 761), induce caspase-3-dependent apoptosis in oral cavity cancer cells. Phytother. Res. 2010, 24 (Suppl. S1), S77-S82. [CrossRef] [PubMed]
121. Niering, P, Michels, G, Watjen, W, Ohler, S, Steffan, B, Chovolou, Y, Kampkotter, A, Proksch, P, Kahl, R. Protective and detrimental effects of kaempferol in rat H4IIE cells: Implication of oxidative stress and apoptosis. Toxicol. Appl. Pharmacol. 2005, 209, 114-122. [CrossRef] [PubMed]
122. Samhan-Arias, A.K, Martin-Romero, F.J, Gutierrez-Merino, C. Kaempferol blocks oxidative stress in cerebellar granule cells and reveals a key role for reactive oxygen species production at the plasma membrane in the commitment to apoptosis. Free Radic. Biol. Med. 2004, 37, 48-61. [CrossRef] [PubMed]
123. Leung, H.W, Lin, C.J, Hour, M.J, Yang, W.H, Wang, M.Y, Lee, H.Z. Kaempferol induces apoptosis in human lung non-small carcinoma cells accompanied by an induction of antioxidant enzymes. Food Chem. Toxicol. 2007, 45, 2005-2013. [CrossRef] [PubMed]
124. Liou, A.K, Clark, R.S, Henshall, D.C, Yin, X.M, Chen, J. To die or not to die for neurons in ischemia, traumatic brain injury and epilepsy: A review on the stress-activated signaling pathways and apoptotic pathways. Prog. Neurobiol. 2003, 69, 103-142. [CrossRef]
125. Liang, S.Q, Marti, T.M, Dorn, P, Froment, L, Hall, S.R, Berezowska, S, Kocher, G, Schmid, R.A, Peng, R.W. Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer. Cell Death Dis. 2015, 6, e1824. [CrossRef] [PubMed]
126. Jo, E, Park, S.J, Choi, Y.S, Jeon, W.K, Kim, B.C. Kaempferol suppresses transforming growth factor-β1-Induced epithelial-to-mesenchymal transition and migration of A549 lung cancer cells by inhibiting Akt1-mediated phosphorylation of Smad3 at Threonine-179. Neoplasia 2015, 17, 525-537. [CrossRef] [PubMed]
127. Gong, J.H, Cho, I.H, Shin, D, Han, S.Y, Park, S.H, Kang, Y.H. Inhibition of airway epithelial-to-mesenchymal transition and fibrosis by kaempferol in endotoxin-induced epithelial cells and ovalbumin-sensitized mice. Lab. Investig. 2014, 94, 297-308. [CrossRef] [PubMed]
128. Sulzmaier, F.J, Ramos, J.W. RSK isoforms in cancer cell invasion and metastasis. Cancer Res. 2013, 73, 6099-6105. [CrossRef] [PubMed]
129. Anderton, M.J, Manson, M.M, Verschoyle, R.D, Gescher, A, Lamb, J.H, Farmer, P.B, Steward, W.P, Williams, M.L. Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. Clin. Cancer Res. 2004, 10, 5233-5241. [CrossRef] [PubMed]
130. Banerjee, S, Kong, D, Wang, Z, Bao, B, Hillman, G.G, Sarkar, F.H. Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): From bench to clinic. Mutat. Res. 2011, 728, 47-66. [CrossRef] [PubMed]
131. Marques, M, Laflamme, L, Benassou, I, Cissokho, C, Guillemette, B, Gaudreau, L. Low levels of 3,31-diindolylmethane activate estrogen receptor alpha and induce proliferation of breast cancer cells in the absence of estradiol. BMC Cancer 2014, 14, 524. [CrossRef] [PubMed]
132. Gong, Y, Sohn, H, Xue, L, Firestone, G.L, Bjeldanes, L.F. 3,31-Diindolylmethane is a novel mitochondrial H(+)-ATP synthase inhibitor that can induce p21(Cip1/Waf1) expression by induction of oxidative stress in human breast cancer cells. Cancer Res. 2006, 66, 4880-4887. [CrossRef] [PubMed]
133. Hong, C, Firestone, G.L, Bjeldanes, L.F. Bcl-2 family-mediated apoptotic effects of 3,31-diindolylmethane (DIM) in human breast cancer cells. Biochem. Pharmacol. 2002, 63, 1085-1097. [CrossRef]
134. Li, Y, Chinni, S.R, Sarkar, F.H. Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Front. Biosci. 2005, 10, 236-243. [CrossRef] [PubMed]
135. Choi, H.J, Lim do, Y, Park, J.H. Induction of G1 and G2/M cell cycle arrests by the dietary compound 3,31-diindolylmethane in HT-29 human colon cancer cells. BMC Gastroenterol. 2009, 9, 39. [CrossRef] [PubMed]
136. Hsu, E.L, Chen, N, Westbrook, A, Wang, F, Zhang, R, Taylor, R.T, Hankinson, O. CXCR4 and CXCL12 down-regulation: A novel mechanism for the chemoprotection of 3,31-diindolylmethane for breast and ovarian cancers. Cancer Lett. 2008, 265, 113-123. [CrossRef] [PubMed]
137. Ahmad, A, Kong, D, Sarkar, S.H, Wang, Z, Banerjee, S, Sarkar, F.H. Inactivation of uPA and its receptor uPAR by 3,31-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration. J. Cell. Biochem. 2009, 107, 516-527. [CrossRef] [PubMed]
138. Ahmad, A, Kong, D, Wang, Z, Sarkar, S.H, Banerjee, S, Sarkar, F.H. Down-regulation of uPA and uPAR by 3,31-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells. J. Cell. Biochem. 2009, 108, 916-925. [CrossRef] [PubMed]
139. Kong, D, Li, Y, Wang, Z, Banerjee, S, Sarkar, F.H. Inhibition of angiogenesis and invasion by 3,31-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res. 2007, 67, 3310-3319. [CrossRef] [PubMed]
140. Kong, D, Sethi, S, Li, Y, Chen, W, Sakr, W.A, Heath, E, Sarkar, F.H. Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes. Prostate 2015, 75, 161-174. [CrossRef] [PubMed]
141. Ahmad, A, Biersack, B, Li, Y, Kong, D, Bao, B, Schobert, R, Padhye, S.B, Sarkar, F.H. Targeted regulation of PI3K/Akt/mTOR/NF-kappaB signaling by indole compounds and their derivatives: Mechanistic details and biological implications for cancer therapy. Anticancer Agents Med. Chem. 2013, 13, 1002-1013. [CrossRef] [PubMed]
142. Lamouille, S, Derynck, R. Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-beta-induced epithelial-mesenchymal transition. Cells Tissues Organs 2011, 193, 8-22. [CrossRef] [PubMed]
143. Sethi, S, Li, Y, Sarkar, F.H. Regulating miRNA by natural agents as a new strategy for cancer treatment. Curr. Drug Targets 2013, 14, 1167-1174. [CrossRef] [PubMed]
144. Melkamu, T, Zhang, X, Tan, J, Zeng, Y, Kassie, F. Alteration ofmicroRNAexpression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis 2010, 31, 252-258. [CrossRef] [PubMed]
145. Li, Y, VandenBoom, T.G., 2nd; Kong, D, Wang, Z, Ali, S, Philip, P.A, Sarkar, F.H. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009, 69, 6704-6712. [CrossRef] [PubMed]
146. Kong, D, Heath, E, Chen, W, Cher, M.L, Powell, I, Heilbrun, L, Li, Y, Ali, S, Sethi, S, Hassan, O, et al. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS ONE 2012, 7, e33729. [CrossRef] [PubMed]
147. Watson, G.W, Beaver, L.M, Williams, D.E, Dashwood, R.H, Ho, E. Phytochemicals from cruciferous vegetables, epigenetics, and prostate cancer prevention. AAPS J. 2013, 15, 951-961. [CrossRef] [PubMed]
148. Li, Y, Kong, D, Ahmad, A, Bao, B, Sarkar, F.H. Targeting bone remodeling by isoflavone and 3,31-diindolylmethane in the context of prostate cancer bone metastasis. PLoS ONE 2012, 7, e33011. [CrossRef] [PubMed]
149. Wu, T, Chen, C, Li, F, Chen, Z, Xu, Y, Xiao, B, Tao, Z. 3,31-Diindolylmethane inhibits the invasion and metastasis of nasopharyngeal carcinoma cells and by regulation of epithelial mesenchymal transition. Exp. Ther. Med. 2014, 7, 1635-1638. [PubMed]
150. Xu, L, Jiang, Y, Zheng, J, Xie, G, Li, J, Shi, L, Fan, S. Aberrant expression of β-catenin and E-cadherin is correlated with poor prognosis of nasopharyngeal cancer. Hum. Pathol. 2013, 44, 1357-1364. [CrossRef] [PubMed]
151. Yellayi, S, Naaz, A, Szewczykowski, M.A, Sato, T, Woods, J.A, Chang, J, Segre, M, Allred, C.D, Helferich, W.G, Cooke, P.S. The phytoestrogen genistein induces thymic and immune changes: A human health concern? Proc. Natl. Acad. Sci. USA 2002, 99, 7616-7621. [CrossRef] [PubMed]
152. Klein, C.B, King, A.A. Genistein genotoxicity: Critical considerations of in vitro exposure dose. Toxicol. Appl. Pharmacol. 2007, 224, 1-11. [CrossRef] [PubMed]
153. You, L. Phytoestrogen genistein and its pharmacological interactions with synthetic endocrine-active compounds. Curr. Pharm. Des. 2004, 10, 2749-2757. [CrossRef] [PubMed]
154. Patisaul, H.B, Jefferson, W. The pros and cons of phytoestrogens. Front. Neuroendocrinol. 2010, 31, 400-419. [CrossRef] [PubMed]